Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217399 · ClinicalTrials.gov registry record · Phase 1
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
A Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00217399 is a Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants, below the 65-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00217399, a Phase 1 study of Stage IV Breast Cancer and Recurrent Breast Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estradiol can cause the growth of breast cancer. Hormone therapy using anastrozole may fight breast cancer by blocking the use of estradiol by the tumor cells. Sometimes when hormone therapy is given, it does not stop the growth of tumor cells. The tumor is said to be resistant to hormone therapy. Giving sorafenib together with anastrozole may reduce drug resistance and allow the tumor cells to be killed. This phase I/II trial is studying the side effects and best dose of sorafenib when given in combination with anastrozole and to see how well they work in treating postmenopausal women with metastatic breast cancer.
Conditions Studied
Interventions
- DRUG anastrozole
- DRUG sorafenib tosylate
Study Locations (1)
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2005-06 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00217399
The ClinicalTrials.gov registry entry for NCT00217399 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (46% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which anastrozole is the first listed.
NCT00217399 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00217399 about?
NCT00217399 is a clinical study titled "Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer". Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estradiol can cause the growth of breast cancer. Hormone therapy using anastrozole may fight breast cancer by blocking the use of estradiol by the tumor cells....
What is the current status of trial NCT00217399?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2005-06. Estimated completion is 2013-01.
What conditions does trial NCT00217399 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer, Recurrent Breast Cancer.
What interventions are being tested in trial NCT00217399?
The interventions under investigation include: anastrozole (DRUG), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00217399?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00217399 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
RECRUITING · Phase 1
-
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
COMPLETED · Phase 1
-
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
COMPLETED · Phase 1
Explore more on PlainTrial
Stage IV Breast Cancer
All registered trials for this condition
Recurrent Breast Cancer
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.